drugset / Trial / NCT05986864
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD. Based on results from the phase 1 dose escalation study, the phase 2 expansion study will be conducted.
Timeline
- Start
- 2024-02-23
- Primary completion
- 2026-01
- Completion
- 2026-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SKG0106 | Gene therapy (AAV / viral vector) | — | Intravitreal |